Drugs / 23vPPV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00714064 | Jun 2006 → Feb 2011 | otitis media with effusion, pneumococcal infection, tympanic membrane disorder | Menzies School of Health Research | Completed | Missed primary |
| Phase 3 | NCT00310349 | Mar 2006 → Jan 2009 | otitis media with effusion, pneumococcal infection, tympanic membrane disorder | University of Melbourne | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23vPPV | “The 23 valent pneumococcal polysaccharide vaccine (23vPPV), is currently recommended for all Indigenous people in the Northern Territory from 15 years of age but uptake among...” NCT00310349 ↗ |
| Known as | 23 valent pneumococcal polysaccharide vaccine | “The 23 valent pneumococcal polysaccharide vaccine (23vPPV), is currently recommended for all Indigenous people in the Northern Territory from 15 years of age but uptake among...” NCT00714064 ↗1“The 23 valent pneumococcal polysaccharide vaccine (23vPPV), is currently recommended for all Indigenous people in the Northern Territory from 15 years of age but uptake among...” NCT00310349 ↗ |
| Modality | Vaccine | “The 23 valent pneumococcal polysaccharide vaccine (23vPPV), is currently recommended for all Indigenous people in the Northern Territory from 15 years of age but uptake among...” NCT00310349 ↗ |